Interleukin-6 as a keystone cytokine in experimental rat models of chemotherapy-induced peripheral neurotoxicity

Read full text
Authors: Olga Tarasiuk, Alessia Chiorazzi, Alberto Argentini, Elisa Ballarini, Annalisa Canta, Valentina Alda Carozzi, E Pozzi, Paola Alberti, Valentina Fabbro, Federico Iseppon, Maria Foti, Cristina Meregalli
Cited by: 3
References: 68

Abstract

Chemotherapy-induced peripheral neurotoxicity (CIPN) is one common side effect associated with antineoplastic agents. Despite its relevance, the underlying mechanisms remain poorly understood. In this study, we explored cytokines and macrophages that contribute to two chronic models of CIPN comparing paclitaxel (PTX)- and oxaliplatin (OHP)-induced CIPN in rats. To detect chemotherapy-induced sensory or neuronal abnormalities behavioral tests, pathological and morphometric analysis were used. To investigate systemic inflammation, a panel including IL-6, IL-1β, IL-2, IL-10, GRO/KC(CXCL1), TNFα, IFNγ were tested in serum. Besides, we analyzed dorsal root ganglia (DRG), caudal nerves and spinal cord mRNA expression of a panel of pro-inflammatory markers IL-6, CCL2 and NLRP3, as well as caudal macrophage infiltration. We evidenced a remarkable difference in caudal macrophage infiltration in PTX- vs. OHP-treated rats, which was associated with serum CXCL1 and to a different IL-6 expression pattern in serum, DRG, spinal cord and caudal nerve. Moreover, CCL2, NLRP3 upregulation was also increased in the caudal nerves in PTX-treated animals. On the contrary, OHP induced IL-6 and CCL2 expression in DRG. Since our results suggest that CXCL1 or IL-6 could be considered as critical lynchpins between inflammation pain and CIPN, targeting early inflammatory events could be a promising therapeutic approach.

Fields of Study & Subjects

Cancer Treatment and Pharmacology Cancer-related cognitive impairment studies Cancer Stress Anesthesia and Immune Response

Publication details

Journal / source
Scientific Reports
Publisher
Springer Science and Business Media LLC
Volume
16
Issue
1
Pages
5127–5127
Publication date
13 January 2026
Language
EN